Metabolism News and Research

Latest Metabolism News and Research

A.P. Pharma second quarter net loss decreases to $1.9 million

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2011 and highlighted its recent corporate progress.

8 Aug 2011

New finding about cell metabolism may have implications for neurodegenerative disorders

Cells are the building blocks of the human body. They are a focus of scientific study, because when things go wrong at the cellular and molecular level the consequences for human health are often significant.

8 Aug 2011

Researchers discover lack of oxygen in the lungs after mold invasion

Researchers led by Montana State University have found a surprising condition that occurs in the lungs after an invasion of a common mold that can cause deadly infections in humans.

6 Aug 2011

New analytical method can develop specific drugs against parasites, bacteria

A team led by Professor Malcolm McConville from the Bio21 Institute, University of Melbourne developed a new analytical method which can be used for many infectious parasites and bacteria.

6 Aug 2011

Simcyp extends application in areas of PD modelling and drug distribution within CNS

Simcyp Limited is pleased to announce significant additions to its flagship simulator in line with priorities established by the Simcyp Consortium of global pharmaceutical companies.

6 Aug 2011

Insulin pumps and other medical devices ‘hackable’

A diabetic security researcher has identified flaws that could allow an attacker to remotely control insulin pumps and alter the readouts of blood-sugar monitors. As a result, diabetics could get too much or too little insulin, a hormone they need for proper metabolism.

5 Aug 2011

New polymer effectively captures nicotine molecules and analogues

Newly synthesized polymer, fitted with molecular pincers of carefully tailored structure, effectively captures nicotine molecules and its analogues.

5 Aug 2011

Takeda, Amylin discontinue pramlintide/metreleptin development program for obesity

Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited today announced that they are discontinuing development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity that comprises pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin.

5 Aug 2011

Dyax initiates ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

Dyax Corp. announced today treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema.

4 Aug 2011

Fatty acids, nutrients during pregnancy can reduce risk of breast cancer in female offspring

Era of Hope conference to feature compelling research examining benefits to daughters During pregnancy, women are counseled to refrain from consuming certain types of foods, beverages and medications in order to avoid jeopardizing the health and development of the fetus.

4 Aug 2011

Siemens receives Health Canada Medical Device License for Biograph mMR

Siemens Canada Healthcare has received a Health Canada Medical Device License for the Biograph mMR.

4 Aug 2011

Researchers discover biological mechanism behind sarcopenia

Researchers at Columbia University Medical Center have discovered the biological mechanism behind age-related loss of muscle strength and identified a drug that may help reverse this process.

3 Aug 2011

AACE's five-tiered approach to elimination of endocrine healthcare disparities

The American Association of Clinical Endocrinologists (AACE) today is announcing the adoption of a new policy reaffirming the Association's commitment to the elimination of endocrine healthcare disparities in the United States.

3 Aug 2011

New alternative to immunosuppressive treatment after kidney transplants without severe side effects

There is now a new alternative to immunosuppressive treatment after kidney transplants which comes without the usual severe side effects. The Medical University was significantly involved in the clinical development of the active ingredient Belatacept and a suitable preparation has now been given EU-wide authorisation.

3 Aug 2011

Autophagy research offers clues to new weight loss treatment

According to a new study when the body is starved brain cells along with other parts of the body begin to eat themselves. The body responds by producing fatty acids, which turn up the hunger signal in the brain and increase the impulse to eat.

3 Aug 2011

GSK, NPS enter agreement to evaluate ronacaleret in new indications

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today reported that it has entered into a new agreement with GlaxoSmithKline (GSK), that terminates and replaces a prior collaborative research and license agreement between NPS and GSK from 1993, which focused on the discovery and development of small molecule antagonists of the calcium receptor that increase secretion of parathyroid hormone.

3 Aug 2011

Nature Biotechnology publishes BGI, GT Life Sciences' study on CHO K1 genome

BGI, the world's largest genomics organization, and GT Life Sciences, Inc., a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, announced today that their collaborative study on the genomic sequence of the Chinese hamster ovary (CHO) K1 cell line was published July 31, 2011 online in Nature Biotechnology.

1 Aug 2011

Stealth presents Bendavia at AHA's Cardiovascular Scientific Sessions

Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with unmet medical needs, presented its lead clinical candidate, Bendavia, during the 2011 American Heart Association's (AHA) Cardiovascular Scientific Sessions.

1 Aug 2011

AACE declares obesity as a disease state

The American Association of Clinical Endocrinologists has declared that there is significant clinical evidence to declare obesity as a disease state. The decision was made in a unanimous vote of the AACE Board of Directors at their quarterly meeting, July 23, in Dallas, TX.

30 Jul 2011

WARFARIN Study initiated to assess utility of genetic testing to reduce warfarin-related adverse events

Iverson Genetic Diagnostics, Inc. announced that the WARFARIN Study was initiated at Colorado Heart & Vascular, P.C. in Denver and other major hospital systems nationwide to assess the utility of genetic testing to determine a personalized warfarin dose for individual patients to reduce their risk of serious bleeding or clotting events.

30 Jul 2011